CCRM
Sujeetha Kaneshalingam has a Master's degree in Biotechnology from McGill University. With a Bachelor of Science in Molecular Biology from the University of Toronto Scarborough, Sujeetha has gained experience in research and development, fermentation protocols, and academic tutoring. Currently working as an Operations Lead at CCRM, Sujeetha also has experience as a Graduate Research Student at the National Research Council Canada exploring the application of the Warburg effect on cell culturing processes. Additionally, Sujeetha has worked as a Fermentation Intern at Lallemand.
CCRM
1 followers
Regenerative Medicine (RM), which aims to harness the power of stem cells, biomaterials and molecules to repair, regenerate or replace diseased cells, tissues and organs, has the promise to treat, manage and perhaps cure some of the most devastating and costly diseases in the world today. Many new and potentially life-changing RM-based treatments never reach patients because they are not successfully moved from the laboratory to a stage where they can be used in medicine. In order to fulfill RM’s promise to treat the many diseases affecting our population, a world-renowned group of stem cell scientists and engineers have come together to form CCRM, a leader in developing and commercializing regenerative medicine and cell therapy technologies. CCRM formally launched on June 14, 2011. CCRM supports the development and commercialization of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy.